The latest idea in NAFLD/NASH pathogenesis

Clinical Journal of Gastroenterology

Volumn 3, Issue 6, 2010, Pages 263-270

  Ono, Masafumi ^a   Okamoto, Nobuto ^a   Saibara, Toshiji ^a  

^a KOCHI MEDICAL SCHOOL   (Japan)

Author keywords

Adipocytokine impairment; Lipotoxicity; Nonalcoholic fatty liver disease; Nonalcoholic steatohepatitis; Oxidative stress; PNPLA3

Indexed keywords

ADIPOCYTOKINE; ADIPONECTIN; ANGIOTENSIN II; FATTY ACID; LEPTIN; TRIACYLGLYCEROL; TUMOR NECROSIS FACTOR;

DNA POLYMORPHISM; ETHNIC DIFFERENCE; FATTY LIVER; GENE; GENETIC ANALYSIS; GLUCOSE HOMEOSTASIS; HUMAN; IRON OVERLOAD; LIFESTYLE; LIPID METABOLISM; LIPOTOXICITY; LIVER CELL; LIVER TOXICITY; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PATHOGENESIS; PNPLA3 GENE; PREVALENCE; PRIORITY JOURNAL; REVIEW; RISK FACTOR;

EID: 78651390992     PISSN: 18657257     EISSN: 18657265     Source Type: Journal    
DOI: 10.1007/s12328-010-0182-9     Document Type: Review

References (92)

1. M Ekstedt LE Franzen UL Mathiesen L Thorelius M Holmqvist G Bodemar, et al. 2006 Long-term follow-up of patients with NAFLD and elevated liver enzymes Hepatology 44 865 873 1:CAS:528:DC%2BD28XhtFyqsrzN 17006923 10.1002/hep.21327 (Pubitemid 46489550)
2. GN Ioannou EJ Boyko SP Lee 2006 The prevalence and predictors of elevated serum aminotransferase activity in the United States in 1999-2002 Am J Gastroenterol 101 76 82 16405537 10.1111/j.1572-0241.2005.00341.x (Pubitemid 43381712)
3. O James C Day 1999 Non-alcoholic steatohepatitis: another disease of affluence Lancet 353 1634 1636 1:STN:280:DyaK1M3ms1yjug%3D%3D 10335777 10.1016/S0140-6736(99)00163-4 (Pubitemid 29224514)
4. M Duvnjak I Lerotić N Barsić V Tomasić L Virović Jukić V Velagić 2007 Pathogenesis and management issues for non-alcoholic fatty liver disease World J Gastroenterol 3 4539 4550
5. H Tilg GS Hotamisligil 2006 Nonalcoholic fatty liver disease: cytokine-adipokine interplay and regulation of insulin resistance Gastroenterology 131 934 945 1:CAS:528:DC%2BD28XhtVKrurbP 16952562 10.1053/j.gastro.2006.05.054 (Pubitemid 44307061)
6. S Caspar-Bauguil B Cousin A Galinier C Segafredo M Nibbelink M André, et al. 2005 Adipose tissues as an ancestral immune organ: site-specific change in obesity FEBS Lett 579 3487 3492 1:CAS:528: DC%2BD2MXlvVWrtr0%3D 15953605 10.1016/j.febslet.2005.05.031 (Pubitemid 40897681)
7. E Rask T Olsson S Söderberg R Andrew DE Livingstone O Johnson, et al. 2001 Tissue-specific dysregulation of cortisol metabolism in human obesity J Clin Endocrinol Metab 86 1418 1421 1:CAS:528:DC%2BD3MXitFWnurk%3D 11238541 10.1210/jc.86.3.1418 (Pubitemid 32323037)
8. Shimomura I, Takahashi M, Tokunaga K, Keno Y, Nakamura T, Yamashita S, et al. Rapid enhancement of acyl-CoA synthetase, LPL, and GLUT-4 mRNAs in adipose tissue of VMH rats. Am J Physiol. 1996;270(6 Pt 1):E995-1002.
9. KL Donnelly CI Smith SJ Schwarzenberg J Jessurun MD Boldt EJ Parks 2005 Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease J Clin Invest 115 1343 1351 1:CAS:528:DC%2BD2MXktFSktLk%3D 15864352
10. F Diraison P Moulin M Beylot 2003 Contribution of hepatic de novo lipogenesis and reesterification of plasma non-esterified fatty acids to plasma triglyceride synthesis during nonalcoholic fatty liver disease Diabetes Metab 29 478 485 1:CAS:528:DC%2BD2cXhtlGiu74%3D 14631324 10.1016/S1262-3636(07)70061-7
11. M Charlton R Sreekumar D Rasmussen K Lindor KS Nair 2002 Apolipoprotein synthesis in nonalcoholic steatohepatitis Hepatology 35 898 904 1:CAS:528:DC%2BD38XjtFSksLg%3D 11915037 10.1053/jhep.2002.32527 (Pubitemid 34258385)
12. L Miele A Grieco A Armuzzi M Candelli A Forgione A Gasbarrini, et al. 2003 Hepatic mitochondrial beta-oxidation in patients with nonalcoholic steatohepatitis assessed by 13C-octanoate breath test Am J Gastroenterol 98 2335 2336 14572600 10.1111/j.1572-0241.2003.07725.x (Pubitemid 37305387)
13. BA Neuschwander-Tetri SH Caldwell 2003 Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference Hepatology 37 1202 1219 12717402 10.1053/jhep.2003.50193 (Pubitemid 36538699)
14. 2 be a risk for obesity-related diseases? J Gastroenterol 38 1022 1023 14614617 10.1007/s00535-003-1209-5 (Pubitemid 37455797)
15. GC Farrell CZ Larter 2006 Nonalcoholic fatty liver disease: from steatosis to cirrhosis Hepatology 43 S99 S112 1:CAS:528:DC%2BD28XhvVSktLo%3D 16447287 10.1002/hep.20973
16. AJ Sanyal 2002 AGA technical review on nonalcoholic fatty liver disease Gastroenterology 123 1705 1725 12404245 10.1053/gast.2002.36572
17. N Yoshiike H Lwin 2005 Epidemiological aspects of obesity and NASH/NAFLD in Japan Hepatol Res 33 77 82 16226488 10.1016/j.hepres.2005.09.008 (Pubitemid 41799779)
18. Amarapurkar DN, Hashimoto E, Lesmana LA, Sollano JD, Chen PJ, Goh KL, Asia-Pacific Working Party on NAFLD. How common is non-alcoholic fatty liver disease in the Asia-Pacific region and are there local differences? J Gastroenterol Hepatol. 2007;22:788.
19. Ueno T, Sugawara H, Sujaku K, Hashimoto O, Tsuji R, Tamaki S, et al. Therapeutic effects of restricted diet and exercise in obese patients with fatty liver. J Hepatol. 1997;27:103.
20. RR Mummadi KS Kasturi S Chennareddygari GK Sood 2008 Effect of bariatric surgery on nonalcoholic fatty liver disease: systematic review and meta-analysis Clin Gastroenterol Hepatol 6 1396 1402 18986848 10.1016/j.cgh.2008.08.012
21. P Angulo JC Keach KP Batts KD Lindor 1999 Independent predictors of liver fibrosis in patients with nonalcoholic steatohepatitis Hepatology 30 1356 1362 1:STN:280:DC%2BD3c%2Fkt1ejtQ%3D%3D 10573511 10.1002/hep.510300604
22. JM Hui A Hodge GC Farrell JG Kench A Kriketos J George 2004 Beyond insulin resistance in NASH: TNF-alpha or adiponectin? Hepatology 40 46 54 1:CAS:528:DC%2BD2cXmtlSgtLY%3D 15239085 10.1002/hep.20280 (Pubitemid 38868922)
23. R Belfort SA Harrison K Brown C Darland J Finch J Hardies, et al. 2006 A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis N Engl J Med 355 2297 2307 1:CAS:528:DC%2BD28Xht1OrtrvI 17135584 10.1056/NEJMoa060326 (Pubitemid 44837778)
24. AJ Sanyal N Chalasani KV Kowdley A McCullough AM Diehl NM Bass, et al. 2010 Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis N Engl J Med 362 1675 1685 1:CAS:528:DC%2BC3cXls1Oltr4%3D 20427778 10.1056/NEJMoa0907929
25. JD Browning LS Szczepaniak R Dobbins P Nuremberg JD Horton JC Cohen, et al. 2004 Prevalence of hepatic steatosis in an urban population in the United States: impact of ethnicity Hepatology 40 1387 1395 15565570 10.1002/hep.20466 (Pubitemid 39657013)
26. A Fraser MP Longnecker DA Lawlor 2007 Prevalence of elevated alanine aminotransferase among US adolescents and associated factors: NHANES 1999-2004 Gastroenterology 133 1814 1820 1:CAS:528:DC%2BD1cXnt1Kqsw%3D%3D 18054554 10.1053/j.gastro.2007.08.077 (Pubitemid 350186161)
27. L Valenti AL Fracanzani P Dongiovanni G Santorelli A Branchi E Taioli, et al. 2002 Tumor necrosis factor alpha promoter polymorphisms and insulin resistance in nonalcoholic fatty liver disease Gastroenterology 122 274 280 1:CAS:528:DC%2BD38XhsVGnsrk%3D 11832442 10.1053/gast.2002.31065
28. S Romeo J Kozlitina C Xing A Pertsemlidis D Cox LA Pennacchio, et al. 2008 Genetic variation in PNPLA3 confers susceptibility to nonalcoholic fatty liver disease Nat Genet 40 1461 1465 1:CAS:528:DC%2BD1cXhsVWgsrrP 18820647 10.1038/ng.257
29. Y Nozaki T Saibara Y Nemoto M Ono N Akisawa S Iwasaki, et al. 2005 Polymorphisms of interleukin 1-beta and beta-3-adrenergic receptor in Japanese patients with nonalcoholic steatohepatitis Alcohol Clin Exp Res 28 106S 110S
30. H Dong J Wang C Li A Hirose Y Nozaki M Takahashi, et al. 2007 The phosphatidylethanolamine N-methyltransferase gene V175M single nucleotide polymorphism confers the susceptibility to NASH in Japanese population J Hepatol 46 915 920 1:CAS:528:DC%2BD2sXjvFamur8%3D 17391797 10.1016/j.jhep.2006.12.012 (Pubitemid 46529040)
31. C Namikawa Z Shu-Ping JR Vyselaar Y Nozaki Y Nemoto M Ono, et al. 2004 Polymorphisms in microsomal triglyceride transfer protein gene and manganese superoxide dismutase gene in Japanese patients with nonalcoholic steatohepatitis J Hepatol 40 781 786 1:CAS:528:DC%2BD2cXjtFOiurw%3D 15094225 10.1016/j.jhep.2004.01.028 (Pubitemid 38507358)
32. K Tokushige M Takakura N Tsuchiya-Matsushita M Taniai E Hashimoto K Shiratori 2007 Influence of TNF gene polymorphisms in Japanese patients with NASH and simple steatosis J Hepatol 46 1104 1110 1:CAS:528:DC%2BD2sXkvFGjsbk%3D 17395331 10.1016/j.jhep.2007.01.028 (Pubitemid 46669735)
33. CM Jenkins DJ Mancuso W Yan HF Sims B Gibson RW Gross 2004 Identification, cloning, expression, and purification of three novel human calcium-independent phospholipase A2 family members possessing triacylglycerol lipase and acylglycerol transacylase activities J Biol Chem 279 48968 48975 1:CAS:528:DC%2BD2cXpslKjsbo%3D 15364929 10.1074/jbc.M407841200 (Pubitemid 39625778)
34. TJ Rydel JM Williams E Krieger F Moshiri WC Stallings SM Brown, et al. 2003 The crystal structure, mutagenesis, and activity studies reveal that patatin is a lipid acyl hydrolase with a Ser-Asp catalytic dyad Biochemistry 42 6696 6708 1:CAS:528:DC%2BD3sXjsleisr4%3D 12779324 10.1021/bi027156r (Pubitemid 36666110)
35. AC Lake Y Sun JL Li JE Kim JW Johnson D Li, et al. 2005 Expression, regulation, and triglyceride hydrolase activity of Adiponutrin family members J Lipid Res 46 2477 2487 1:CAS:528:DC%2BD2MXhtF2iu7nP 16150821 10.1194/jlr.M500290-JLR200 (Pubitemid 41532536)
36. S Romeo F Sentinelli S Dash GS Yeo DB Savage F Leonetti, et al. 2009 Morbid obesity exposes the association between PNPLA3 I148M (rs738409) and indices of hepatic injury in individuals of European descent Int J Obes (Lond) 34 190 194 10.1038/ijo.2009.216
37. LE Johansson J Hoffstedt H Parikh E Carlsson M Wabitsch AG Bondeson, et al. 2006 Variation in the adiponutrin gene influences its expression and associates with obesity Diabetes 55 826 833 1:CAS:528:DC%2BD28XisVWisb0%3D 16505250 10.2337/diabetes.55.03.06.db05-1075
38. YM Liu M Moldes JP Bastard E Bruckert N Viguerie B Hainque, et al. 2004 Adiponutrin: a new gene regulated by energy balance in human adipose tissue J Clin Endocrinol Metab 89 2684 2689 1:CAS:528:DC%2BD2cXmtlGqtbs%3D 15181042 10.1210/jc.2003-031978 (Pubitemid 38766350)
39. M Moldes G Beauregard M Faraj N Peretti PH Ducluzeau M Laville, et al. 2006 Adiponutrin gene is regulated by insulin and glucose in human adipose tissue Eur J Endocrinol 155 461 468 1:CAS:528:DC%2BD28XhtVClurzN 16914601 10.1530/eje.1.02229 (Pubitemid 44463953)
40. M Faraj G Beauregard E Loizon M Moldes K Clement Y Tahiri, et al. 2006 Insulin regulation of gene expression and concentrations of white adipose tissue-derived proteins in vivo in healthy men: relation to adiponutrin J Endocrinol 191 427 435 1:CAS:528:DC%2BD28XhtlejsL3K 17088412 10.1677/joe.1.06659 (Pubitemid 44830618)
41. A Kotronen LE Johansson LM Johansson C Roos J Westerbacka A Hamsten, et al. 2009 A common variant in PNPLA3, which encodes adiponutrin, is associated with liver fat content in humans Diabetologia 52 1056 1060 1:CAS:528: DC%2BD1MXlt1Gqtb8%3D 19224197 10.1007/s00125-009-1285-z
42. A Kotronen M Peltonen A Hakkarainen K Sevastianova R Bergholm LM Johansson, et al. 2009 Prediction of non-alcoholic fatty liver disease and liver fat using metabolic and genetic factors Gastroenterology 137 865 872 1:CAS:528:DC%2BD1MXhtF2isrbK 19524579 10.1053/j.gastro.2009.06.005
43. EK Speliotes JL Butler CD Palmer BF Voight JN Hirschhorn GIANT Consortium MIGen Consortium NASH CRN 2010 PNPLA3 variants specifically confer increased risk for histologic nonalcoholic fatty liver disease but not metabolic disease Hepatology 52 904 912 1:CAS:528:DC%2BC3cXhtFyitr%2FM 20648472 10.1002/hep.23768
44. Y Rotman C Koh JM Zmuda DE Kleiner TJ Liang NASH CRN 2010 The association of genetic variability in patatin-like phospholipase domain-containing protein 3 (PNPLA3) with histological severity of nonalcoholic fatty liver disease Hepatology 52 894 903 1:CAS:528:DC%2BC3cXhtFyitr7F 20684021 10.1002/hep.23759
45. NJ Barshop CB Sirlin JB Schwimmer JE Lavine 2008 Review article: epidemiology, pathogenesis and potential treatments of paediatric nonalcoholic fatty liver disease Aliment Pharmacol Ther 28 13 24 1:CAS:528: DC%2BD1cXovFelsbo%3D 18397387 10.1111/j.1365-2036.2008.03703.x (Pubitemid 351782810)
46. A Alisi M Manco N Panera V Nobili 2009 Association between type two diabetes and non-alcoholic fatty liver disease in youth Ann Hepatol 8 Suppl 1 S44 S50 19381124
47. HM Patton C Sirlin C Behling M Middleton JB Schwimmer JE Lavine 2006 Pediatric nonalcoholic fatty liver disease: a critical appraisal of current data and implications for future research J Pediatr Gastroenterol Nutr 43 413 427 17033514 10.1097/01.mpg.0000239995.58388.56 (Pubitemid 44568999)
48. D Papandreou I Rousso I Mavromichalis 2007 Update on non-alcoholic fatty liver disease in children Clin Nutr 26 409 415 1:CAS:528:DC%2BD2sXotlaisro%3D 17449148 10.1016/j.clnu.2007.02.002 (Pubitemid 47091479)
49. W Dunn JB Schwimmer 2008 The obesity epidemic and nonalcoholic fatty liver disease in children Curr Gastroenterol Rep 10 67 72 18417045 10.1007/s11894-008-0011-1
50. M Manco M Marcellini R Devito D Comparcola MR Sartorelli V Nobili 2008 Metabolic syndrome and liver histology in paediatric nonalcoholic steatohepatitis Int J Obes (Lond) 32 381 387 1:STN:280:DC%2BD1c7itVequw%3D%3D 10.1038/sj.ijo.0803711 (Pubitemid 351271778)
51. L Valenti A Alisi E Galmozzi A Bartuli B Del Menico A Alterio, et al. 2010 I148M patatin-like phospholipase domain-containing 3 gene variant and severity of pediatric nonalcoholic fatty liver disease Hepatology 52 4 1274 1280 1:CAS:528:DC%2BC3cXhtlejsrjN 20648474 10.1002/hep.23823
52. W Chen B Chang L Li L Chan 2010 Patatin-like phospholipase domain-containing 3/adiponutrin deficiency in mice is not associated with fatty liver disease Hepatology 52 1134 1142 1:CAS:528:DC%2BC3cXhtFyitr3M 20648554 10.1002/hep.23812
53. S He C McPhaul JZ Li R Garuti L Kinch NV Grishin, et al. 2010 A sequence variation (I148M) in PNPLA3 associated with nonalcoholic fatty liver disease disrupts triglyceride hydrolysis J Biol Chem 285 6706 6715 1:CAS:528: DC%2BC3cXit1aitrg%3D 20034933 10.1074/jbc.M109.064501
54. CP Day OF James 1998 Steatohepatitis: a tale of two "hits"? Gastroenterology 114 842 845 1:STN:280:DyaK1c3htFartQ%3D%3D 9547102 10.1016/S0016-5085(98)70599-2 (Pubitemid 28160420)
55. Y Sumida T Nakashima T Yoh M Furutani A Hirohama Y Kakisaka, et al. 2003 Serum thioredoxin levels as a predictor of steatohepatitis in patients with nonalcoholic fatty liver disease J Hepatol 38 32 38 1:CAS:528: DC%2BD38XptlSqt7k%3D 12480557 10.1016/S0168-8278(02)00331-8 (Pubitemid 36078521)
56. Y Ikura M Ohsawa T Suekane H Fukushima H Itabe H Jomura, et al. 2006 Localization of oxidized phosphatidylcholine in nonalcoholic fatty liver disease: impact on disease progression Hepatology 43 506 514 1:CAS:528:DC%2BD28XjtVKqsbk%3D 16496325 10.1002/hep.21070
57. AJ Sanyal C Campbell-Sargent F Mirshahi WB Rizzo MJ Contos RK Sterling, et al. 2001 Nonalcoholic steatohepatitis: association of insulin resistance and mitochondrial abnormalities Gastroenterology 120 1183 1192 1:CAS:528: DC%2BD3MXjtVeqsb8%3D 11266382 10.1053/gast.2001.23256
58. D Pessayre A Berson B Fromenty A Mansouri 2001 Mitochondria in steatohepatitis Semin Liver Dis 21 57 69 1:CAS:528:DC%2BD3MXivFGnsL4%3D 11296697 10.1055/s-2001-12929
59. IA Leclercq GC Farrell J Field DR Bell FJ Gonzalez GR Robertson 2000 CYP2E1 and CYP4A as microsomal catalysts of lipid peroxides in murine nonalcoholic steatohepatitis J Clin Invest 105 1067 1075 1:CAS:528: DC%2BD3cXisFOltbc%3D 10772651 10.1172/JCI8814
60. AM Diehl 2001 Nonalcoholic fatty liver disease: implications for alcoholic liver disease pathogenesis Alcohol Clin Exp Res 25 Suppl 8S 14S 1:CAS:528:DC%2BD3MXktlerur0%3D 11391044 10.1097/00000374-200105051-00004
61. K Schulze-Osthoff AC Bakker B Vanhaesebroeck R Beyaert WA Jacob W Fiers 1992 Cytotoxic activity of TNF is mediated by early damage of mitochondrial functions J Biol Chem 267 5317 5323 1:CAS:528:DyaK38Xhslajtr0%3D 1312087
62. RF Schwabe DA Brenner 2006 Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways Am J Physiol Gastrointest Liver Physiol 290 G583 G589 1:CAS:528:DC%2BD28Xks1Sls7Y%3D 16537970 10.1152/ajpgi.00422.2005
63. L Malaguarnera R Madeddu E Palio N Arena M Malaguarnera 2005 Heme oxygenase-1 levels and oxidative stress-related parameters in non-alcoholic fatty liver disease patients J Hepatol 42 585 591 1:CAS:528:DC%2BD2MXitFyqsr8%3D 15763346 10.1016/j.jhep.2004.11.040 (Pubitemid 40342940)
64. MD Weltman GC Farrell P Hall M Ingelman-Sundberg C Liddle 1998 Hepatic cytochrome P450 2E1 is increased in patients with nonalcoholic steatohepatitis Hepatology 27 128 133 1:CAS:528:DyaK1cXlvVeqtw%3D%3D 9425928 10.1002/hep.510270121 (Pubitemid 28041545)
65. JM Schattenberg Y Wang R Singh RM Rigoli MJ Czaja 2005 Hepatocyte CYP2E1 overexpression and steatohepatitis lead to impaired hepatic insulin signaling J Biol Chem 280 9887 9894 1:CAS:528:DC%2BD2MXit1erurs%3D 15632182 10.1074/jbc.M410310200 (Pubitemid 40395836)
66. HL Bonkovsky Q Jawaid K Tortorelli P LeClair J Cobb RW Lambrecht, et al. 1999 Non-alcoholic steatohepatitis and iron: increased prevalence of mutations of the HFE gene in non-alcoholic steatohepatitis J Hepatol 31 421 429 1:CAS:528:DyaK1MXmtFKgu7c%3D 10488699 10.1016/S0168-8278(99)80032-4 (Pubitemid 29408723)
67. A Riquelme A Soza L Nazal G Martínez M Kolbach A Patillo, et al. 2004 Histological resolution of steatohepatitis after iron depletion Dig Dis Sci 49 1012 1015 15309893 10.1023/B:DDAS.0000034564.68307.39 (Pubitemid 39012288)
68. JD Browning JD Horton 2004 Molecular mediators of hepatic steatosis and liver injury J Clin Invest 114 147 152 1:CAS:528:DC%2BD2cXlvFWms7c%3D 15254578
69. O Cheung AJ Sanyal 2008 Abnormalities of lipid metabolism in nonalcoholic fatty liver disease Semin Liver Dis 28 351 359 1:CAS:528:DC%2BD1cXhsVKju7fE 18956291 10.1055/s-0028-1091979
70. CJ McClain S Barve I Deaciuc 2007 Good fat/bad fat Hepatology 45 1343 1346 1:CAS:528:DC%2BD2sXnvFalt7g%3D 17538963 10.1002/hep.21788 (Pubitemid 46918317)
71. K Yamaguchi L Yang S McCall J Huang XX Yu SK Pandey, et al. 2007 Inhibiting triglyceride synthesis improves hepatic steatosis but exacerbates liver damage and fibrosis in obese mice with nonalcoholic steatohepatitis Hepatology 45 1366 1374 1:CAS:528:DC%2BD2sXnvFaltLw%3D 17476695 10.1002/hep.21655 (Pubitemid 46918320)
72. S Cases SJ Smith YW Zheng HM Myers SR Lear E Sande, et al. 1998 Identification of a gene encoding an acyl CoA:diacylglycerol acyltransferase, a key enzyme in triacylglycerol synthesis Proc Natl Acad Sci USA 95 13018 13023 1:CAS:528:DyaK1cXntFWktbg%3D 9789033 10.1073/pnas.95.22.13018 (Pubitemid 28509516)
73. S Cases SJ Stone P Zhou E Yen B Tow KD Lardizabal, et al. 2001 Cloning of DGAT2, a second mammalian diacylglycerol acyltransferase, and related family members J Biol Chem 276 38870 38876 1:CAS:528:DC%2BD3MXnvVenur8%3D 11481335 10.1074/jbc.M106219200
74. HC Chen 2006 Enhancing energy and glucose metabolism by disrupting triglyceride synthesis: lessons from mice lacking DGAT1 Nutr Metab (Lond) 3 10 10.1186/1743-7075-3-10
75. D Pessayre B Fromenty A Mansouri 2004 Mitochondrial injury in steatohepatitis Eur J Gastroenterol Hepatol 16 1095 1105 1:CAS:528: DC%2BD2cXos1aqs7g%3D 15489566 10.1097/00042737-200411000-00003 (Pubitemid 39488778)
76. J Crespo A Cayón P Fernández-Gil M Hernández-Guerra M Mayorga A Domínguez-Díez, et al. 2001 Gene expression of tumor necrosis factor alpha and TNF-receptors, p55 and p75, in nonalcoholic steatohepatitis patients Hepatology 34 1158 1163 1:CAS:528: DC%2BD38XhslWisA%3D%3D 11732005 10.1053/jhep.2001.29628 (Pubitemid 33096588)
77. LJ Old 1985 Tumor necrosis factor (TNF) Science 230 630 632 1:STN:280:DyaL28%2FhvVyltQ%3D%3D 2413547 10.1126/science.2413547
78. GS Hotamisligil P Arner JF Caro RL Atkinson BM Spiegelman 1995 Increased adipose tissue expression of tumor necrosis factor-alpha in human obesity and insulin resistance J Clin Invest 95 2409 2415 1:CAS:528:DyaK2MXltlWru70%3D 7738205 10.1172/JCI117936
79. H Ruan HF Lodish 2003 Insulin resistance in adipose tissue: direct and indirect effects of tumor necrosis factor-alpha Cytokine Growth Factor Rev 14 447 455 1:CAS:528:DC%2BD3sXms1Oqtr8%3D 12948526 10.1016/S1359-6101(03)00052-2 (Pubitemid 37099456)
80. GS Hotamisligil A Budavari D Murray BM Spiegelman 1994 Reduced tyrosine kinase activity of the insulin receptor in obesity-diabetes: central role of tumor necrosis factor-alpha J Clin Invest 94 1543 1549 1:CAS:528: DyaK2cXmt1OrtL8%3D 7523453 10.1172/JCI117495
81. KT Uysal SM Wiesbrock GS Hotamisligil 1998 Functional analysis of tumor necrosis factor (TNF) receptors in TNF alpha-mediated insulin resistance in genetic obesity Endocrinology 139 4832 4838 1:CAS:528:DyaK1cXns1ehsbk%3D 9832419 10.1210/en.139.12.4832
82. KT Uysal SM Wiesbrock MW Marino GS Hotamisligil 1997 Protection from obesity-induced insulin resistance in mice lacking TNF-alpha function Nature 389 6651 610 614 1:CAS:528:DyaK2sXmslWgu7k%3D 9335502 10.1038/39335 (Pubitemid 27446179)
83. P Arner 2003 The adipocyte in insulin resistance: key molecules and the impact of the thiazolidinediones Trends Endocrinol Metab 14 137 145 1:CAS:528:DC%2BD3sXisV2nsL8%3D 12670740 10.1016/S1043-2760(03)00024-9 (Pubitemid 36733912)
84. J Spranger A Kroke M Möhlig MM Bergmann M Ristow H Boeing, et al. 2003 Adiponectin and protection against type 2 diabetes mellitus Lancet 361 9353 226 228 1:CAS:528:DC%2BD3sXkvVOlsQ%3D%3D 12547549 10.1016/S0140-6736(03)12255-6 (Pubitemid 36126226)
85. G Targher L Bertolini S Rodella G Zoppini L Scala L Zenari, et al. 2006 Associations between plasma adiponectin concentrations and liver histology in patients with nonalcoholic fatty liver disease Clin Endocrinol (Oxf) 64 679 683 1:CAS:528:DC%2BD28XmvVyls7g%3D 10.1111/j.1365-2265.2006.02527.x (Pubitemid 43775007)
86. A Xu Y Wang H Keshaw LY Xu KS Lam GJ Cooper 2003 The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice J Clin Invest 112 91 100 1:CAS:528:DC%2BD3sXlt1Krt7c%3D 12840063
87. G Musso R Gambino G Biroli M Carello E Fagà G Pacini, et al. 2005 Hypoadiponectinemia predicts the severity of hepatic fibrosis and pancreatic beta-cell dysfunction in nondiabetic nonobese patients with nonalcoholic steatohepatitis Am J Gastroenterol 100 2438 2446 1:CAS:528:DC%2BD2MXht1OgsrfK 16279898 10.1111/j.1572-0241.2005.00297.x
88. P Angulo LM Alba LM Petrovic LA Adams KD Lindor MD Jensen 2004 Leptin, insulin resistance, and liver fibrosis in human nonalcoholic fatty liver disease J Hepatol 41 943 949 1:CAS:528:DC%2BD2cXhtVCgsLzF 15582127 10.1016/j.jhep.2004. 08.020 (Pubitemid 39575661)
89. IA Leclercq GC Farrell R Schriemer GR Robertson 2002 Leptin is essential for the hepatic fibrogenic response to chronic liver injury J Hepatol 37 206 213 1:CAS:528:DC%2BD38XlsVKjsr8%3D 12127425 10.1016/S0168-8278(02)00102-2 (Pubitemid 34833082)
90. R Bataller RF Schwabe YH Choi L Yang YH Paik J Lindquist, et al. 2003 NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis J Clin Invest 112 1383 1394 1:CAS:528: DC%2BD3sXovVGqs7s%3D 14597764
91. S Yokohama M Yoneda M Haneda S Okamoto M Okada K Aso, et al. 2004 Therapeutic efficacy of an angiotensin II receptor antagonist in patients with nonalcoholic steatohepatitis Hepatology 40 1222 1225 1:CAS:528: DC%2BD2cXhtVCgt7jK 15382153 10.1002/hep.20420 (Pubitemid 39425579)
92. A Hirose M Ono T Saibara Y Nozaki K Masuda A Yoshioka, et al. 2007 Angiotensin II type 1 receptor blocker inhibits fibrosis in rat nonalcoholic steatohepatitis Hepatology 45 1375 1381 1:CAS:528:DC%2BD2sXnvFaltLo%3D 17518368 10.1002/hep.21638 (Pubitemid 46918321)